NCT07085182View on ClinicalTrials.gov

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 13, 2024

Primary Completion Date

December 10, 2027

Study Completion Date

December 10, 2028

Conditions
NSCLCTislelizumabChemotherapyHypofractionated Radiotherapy
Interventions
DRUG

SBRT combined with Tislelizumab followed by Tislelizumab

SBRT:3-10Gy/F, once daily, 5 times a week; Tislelizumab(200mg,iv,q3w):Tislelizumab was added after five sessions of SBRT radiotherapy.

Trial Locations (1)

250000

RECRUITING

Zibo Municipal Hospital, Zibo

All Listed Sponsors
lead

Zibo Municipal Hospital

OTHER